Skip to main content

Table 3 Treatment toxicitya

From: A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma

Grade 1 2 3 4 5
N = 53 No. (%) No. (%) No. (%) No. (%) No. (%)
Neutropaenia 21 (39.6) 8 (15.0) 3 (5.6) 1 (1.8) 0
Thrombocytopaenia 9 (16.9) 4 (7.5) 1 (1.8) 0 0
Anaemia 21 (39.6) 8 (15.0) 0 1 (1.8) 0
Vomiting 9 (16.9) 3 (5.6) 1 (1.8) 0 0
Feverb 7 (13.2) 1 (1.8) 0 0 0
Fatigue 14 (26.4) 3 (5.6) 3 (5.6) 1 (1.8) 0
Alopecia 9 (16.9) 6 (11.3) 0 0 0
Hypoalbuminaemia 7 (13.2) 2 (3.7) 0 0 0
ALTc 9 (16.9) 3 (5.6) 1 (1.8) 0 0
Anorexia 16 (30.1) 11 (20.7) 1 (1.8) 0 0
Dermatitis radiation 10 (18.8) 5 (9.4) 1 (1.8) 0 0
Oesophagitis 25 (47.1) 16 (30.1) 5 (9.4) 0 0
Hypocalcaemia 6 (11.3) 2 (3.7) 0 0 0
Hypomagnesaemia 1 (1.8) 0 0 0 0
Hyponatraemia 2 (3.7) 0 2 (3.7) 0 0
Hypophosphataemia 3 (5.6) 0 0 0 0
Constipation 2 (3.7) 2 (3.7) 0 0 0
Diarrhea 3 (5.6) 0 0 0 0
Peripheral sensory neuropathy 13 (24.5) 4 (7.5) 0 0 0
Pneumonitis 5 (9.4) 0 1 (1.8) 0 2 (3.7)
Hypokalaemia 3 (5.6) 0 1 (1.8) 0 0
Hoarseness 5 (9.4) 0 0 0 0
Ventricular arrhythmia 1 (1.8) 0 0 0 0
Creatinine increased 1 (1.8) 0 0 0 0
Pericardial effusion 2 (3.7) 0 0 0 0
  1. aToxicity was grade according to the National Cancer Institute Common Toxicity Criteria, version 3.0; bOf the 8 patients, 3 patients experienced febrile neutropenia; CAlanine aminotransferase increased